Dey To Pay $280M To End Drug Price Inflation Suit
Mylan Inc. subsidiary Dey Inc. on Monday agreed to pay $280 million to settle allegations that it violated the False Claims Act by inflating prices for its pharmaceutical products, marking the...To view the full article, register now.
Already a subscriber? Click here to view full article